Premal Thaker, MD, MS, discusses IMNN-001 boosts overall survival in advanced ovarian cancer, with bigger gains alongside PARP inhibitors, as phase 3 OVATION 3 ramps up.
Premal Thaker, MD, MS
Premal Thaker, MD, MS, is a gynecologic oncologist at Siteman Cancer Center, Washington University in St. Louis.
Articles by Premal Thaker, MD, MS
Dr Premal Thaker reports IMNN-001 shows early survival benefit in ovarian cancer by activating immune response directly in the tumor environment.
Premal Thaker, MD, MS, discusses important implications and takeaways of the phase 1/2 OVATION study of IMMN-1 in addition to chemotherapy for the treatment of newly diagnosed epithelial ovarian cancer.
Latest Updated Articles
IMNN-001: A Broader Approach to ImmunotherapyMay 5th 2026
